EYES / Vivani Medical Inc - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 Vivani Medical,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission

Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study i

Exhibit 99.1 Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study of NPM-139 to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36747 Vivani Medical, Inc.

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical

Exhibit 99.1 Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelera

Share Purchase Agreement, dated as of August 11, 2025.

Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of August 11, 2025 (the “Execution Date”), by and between Vivani Medical, Inc., a Delaware corporation (the “Company”), Gregg G Williams 2006 Irrevocable Trust and SDVF, LLC (each a “Purchaser” and collectively, the “Purchasers”). The Company and the Purchasers are each hereafter referred to individu

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission Fi

Corporate Slides as of August 13, 2025.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission Fil

Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115 LIBERATE-

Exhibit 99.1 Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115 LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

Exenatide implant reduces liver fat by 82% in obese mice after 12 weeks Liver fat reduction in high fat diet-induced obese mice. Liver fat % area for exenatide implant vs sham implant 12 weeks after a single administration. Liver fat % area is calcul

Exhibit 99.1 Exenatide implant reduces liver fat by 82% in obese mice after 12 weeks Liver fat reduction in high fat diet-induced obese mice. Liver fat % area for exenatide implant vs sham implant 12 weeks after a single administration. Liver fat % area is calculated using Oil Red O (ORO) staining. Values are mean ± SE. These results are numerically consistent with a similar investigation in which

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer

Exhibit 99.1 Vivani Medical Appoints Anthony Baldor as Chief Financial Officer ALAMEDA, Calif., June 11, 2025 - (Globe Newswire) - Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid A. Ma

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing int

Exhibit 99.1 Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion® Visual Cortical Prosthesis System to provid

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on

Exhibit 99.1 Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025 Announced new $3M equity financ

Vivani Medical, Inc. Amended and Restated Executive Severance Policy.

Exhibit 10.2 VIVANI MEDICAL, INC. AMENDED AND RESTATED EXECUTIVE SEVERANCE POLICY 1. Introduction Vivani Medical, Inc. (the “Company”) has adopted this Amended and Restated Executive Severance Policy (the “Policy”) as of April [29], 2025 to provide certain severance pay, benefits and equity treatment to a Covered Individual who is involuntarily terminated by the Company (or its successor) in conne

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36747 Vivani Medical, Inc.

Exenatide implant reduces liver fat by 82% in obese mice after 12 weeks Liver fat reduction in high fat diet-induced obese mice. Liver fat % area for exenatide implant vs sham implant 12 weeks after a single administration. Liver fat % area is calcul

Exenatide implant reduces liver fat by 82% in obese mice after 12 weeks Liver fat reduction in high fat diet-induced obese mice.

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

Share Purchase Agreement, dated as of May 12, 2025.

Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of May 12, 2025 (the “Execution Date”), by and between Vivani Medical, Inc., a Delaware corporation (the “Company”) and Gregg G Williams 2006 Irrevocable Trust (the “Purchaser”). The Company and the Purchaser are each hereafter referred to individually as a “Party” and together as the “Parties.” RECI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabol

Exhibit 99.1 Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans ALAMEDA, Calif. and SAN FRANCISCO, Calif. — April 15, 2025 — Vivani Medical, Inc. (NASDAQ: VANI) ("Viv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission Fil

Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Vivani Medical, Inc.

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight

Exhibit 99.1 Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable to inject

Share Purchase Agreement by and between the Company and Gregg Williams, dated November 8, 2024.

Exhibit 10.9 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of November 8, 2024 (the “Execution Date”), by and between Vivani Medical, Inc., a Delaware corporation (the “Company”) and Gregg Williams (the “Purchaser”). The Company and the Purchaser are each hereafter referred to individually as a “Party” and together as the “Parties.” RECITALS WHEREAS, subject

Nasdaq: VANI www.vivani.com March 2025 Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Secu

Exhibit 99.2 Nasdaq: VANI www.vivani.com March 2025 Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements

Insider Trading Policy.

Exhibit 19.1 Quality System Standard Operating Procedure Document Number SOP 101504 Revision 04 Page 1 of 17 VIVANI MEDICAL, INC. AMENDED AND RESTATED INSIDER TRADING POLICY Vivani Medical, Inc. (the “Company”) has adopted the following policy and procedures for securities trading by Company directors and employees as amended and/or restated from time to time, (our “Insider Trading Policy”). Our I

Share Purchase Agreement, dated as of March 26, 2025.

Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of March 26, 2025 (the “Execution Date”), by and between Vivani Medical, Inc., a Delaware corporation (the “Company”) and Gregg G Williams 2006 Irrevocable Trust (the “Purchaser”). The Company and the Purchaser are each hereafter referred to individually as a “Party” and together as the “Parties.” RE

Vivani Medical Announces $8.25M Private Placement Equity Financing Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semagl

Exhibit 99.1 Vivani Medical Announces $8.25M Private Placement Equity Financing Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management Alameda, CA - (GLOBE NEWSWIRE) – March 26, 2025 – Vivani Medical, Inc. (Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission Fil

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing NanoPortalTM technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinic

Exhibit 99.1 Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing NanoPortalTM technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administr

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults Miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management NP

Exhibit 99.2 Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults Miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management NPM-115 has demonstrated comparable preclinical weight loss to injections of semaglutide, the active ingredient in Ozempic®/Wegovy® Rapid f

About Cortigent, Inc.

Exhibit 99.1 Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent’s Orion® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results Formerly Second Sight Medi

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 (March 12, 2025) Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results Regulatory approval to initiate first-in-human study with a miniature, ultra long-acting GLP-1 (exenatide) implant in obese or ove

Exhibit 99.1 Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results Regulatory approval to initiate first-in-human study with a miniature, ultra long-acting GLP-1 (exenatide) implant in obese or overweight individuals in Australia Miniature, ultra long-acting GLP-1 implant produced sham-implant adjusted liver fat reduction of 82% in

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes.Nasdaq: VANI WWW.Vivani.com

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes.Nasdaq: VANI WWW.Vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 VIVANI MEDICAL,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Vivani Medical, Inc.

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

Exhibit 99.1 FOR IMMEDIATE RELEASE Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024 ALAMEDA, Calif. – (BUSINESS NEWSWIRE) – October 22, 2024 – Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced t

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission F

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

Exhibit 99.1 FOR IMMEDIATE RELEASE Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, the active ingredient in Ozempic®/Wegovy®, with twice- yearly administration Study

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Vivani Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

Exhibit 99.1 FOR IMMEDIATE RELEASE Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024 ALAMEDA, Calif. – (BUSINESS NEWSWIRE) – September 23, 2024 – Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Vivani Medical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single adminis

Exhibit 99.1 FOR IMMEDIATE RELEASE Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously announced sham-implant adjusted preclinical weight loss

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission

www.vivani.com Vivani Medical, Inc. Guaranteed Adherence. Adherence Adherence. August 2024

www.vivani.com Vivani Medical, Inc. Guaranteed Adherence. Adherence Adherence. August 2024 . Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" c

Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results Initiation of the NPM-115 clinical program expected in the fourth quarter of 2024 with a first-in-human study evaluating a miniature, subdermal GLP-1 (exenatide

Exhibit 99.1 Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results Initiation of the NPM-115 clinical program expected in the fourth quarter of 2024 with a first-in-human study evaluating a miniature, subdermal GLP-1 (exenatide) implant in obese or overweight patients FDA provided clearance of the Investigational New Drug Application for NPM-119, providing furth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Vivani Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 VIVANI MEDICAL, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission Fi

Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115 Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024 The NPM-115

Exhibit 99.1 FOR IMMEDIATE RELEASE Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115 Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024 The NPM-115 clinical program will consist of a series of studies designed to support the development of Vivani’s miniature, 6-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 Vivani Medical, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 VIVANI MEDICAL, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission File

Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant NPM-119 is being studied to address medication non-adherence and potentially improve tole

Exhibit 99.1 Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant NPM-119 is being studied to address medication non-adherence and potentially improve tolerability issues associated with oral and injectable type 2 diabetes medications, by providing long-term therapeutic delivery of exenatide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 Vivani Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Vivani Medical, Inc.

Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results Company continues advancing the development of miniature, long-term GLP-1 implants for the treatment of chronic weight management in obese or overweight patients

Exhibit 99.1 Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results Company continues advancing the development of miniature, long-term GLP-1 implants for the treatment of chronic weight management in obese or overweight patients, type 2 diabetes, and other chronic diseases Stable financial position supports operations into the second half of 2025 and potential de

Nasdaq: VANI www.vivani.com Vivani Medical, Inc. Guaranteed Adherence, Better Outcomes. May 2024

Exhibit 99.2 Nasdaq: VANI www.vivani.com Vivani Medical, Inc. Guaranteed Adherence, Better Outcomes. May 2024 Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27Aof the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the

Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission File

Non-Employee Director Compensation Policy.

Exhibit 10.1 Non-Employee Director Compensation Policy Directors of Vivani Medical, Inc. (the “Company”) that are not employees of the Company or one of its subsidiaries receive compensation for their services to the Board of Directors of the Company (the “Board”) and related committees as set forth below. Annual Cash Retainer Fees Effective September 1, 2022, the annual cash retainer fees for non

As filed with the Securities and Exchange Commission on May 2, 2024

As filed with the Securities and Exchange Commission on May 2, 2024 Registration Statement No.

Vivani Medical, Inc. 1350 S. Loop Road Alameda, CA 94502

Vivani Medical, Inc. 1350 S. Loop Road Alameda, CA 94502 May 2, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Juan Grana Re: Vivani Medical, Inc. Registration Statement on Form S-3 (File No. 333-278869) Request for Acceleration of Effective Date To whom it may concern: Pursuant to Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission Fil

Open Market Sale AgreementSM by and between the Company and Jefferies LLC, dated April 22, 2024 (incorporated by reference to Exhibit 1.2 of the Company’s Registration Statement on Form S-3 filed on April 22, 2024).

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM April 22, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Vivani Medical, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stoc

Form of indenture for subordinated debt securities and the related form of subordinated debt security.

Exhibit 4.4 VIVANI MEDICAL, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [] Subordinated Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vivani Medical, Inc.

As filed with the Securities and Exchange Commission on April 22, 2024

As filed with the Securities and Exchange Commission on April 22, 2024 Registration No.

Form of indenture for senior debt securities and the related form of senior debt security.

Exhibit 4.3 VIVANI MEDICAL, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Se

Compensation Recovery Policy

Exhibit 97.1 VIVANI MEDICAL, INC. COMPENSATION RECOVERY POLICY Adopted as of August 10, 2023 Vivani Medical, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former Exec

Description of Capital Stock.

Exhibit 4.5 DESCRIPTION OF CAPITAL STOCK The following description summarizes certain important terms of the capital stock of Vivani Medical, Inc. (the “Company,” “Vivani,” “we,” “us,” and “our”) as of the date of this Annual Report on Form 10-K (the “Annual Report” or “Form 10-K”) as specified in our Certification of Incorporation (the “Certificate of Incorporation”) and our Bylaws (the “Bylaws”)

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Strategic shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management Positive NPM-115 (exenati

Exhibit 99.1 Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Strategic shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management Positive NPM-115 (exenatide implant) preclinical weight loss data comparable to semaglutide, active ingredient in Ozempic®/Wegovy® $15 million financing round ena

Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed on March 26, 2024 (File No. 001-36747)).

Exhibit 4.1

List of Registrant’s Subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES OF THE REGISTRANT The following are the subsidiaries of Vivani Medical, Inc, omitting certain subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary: Name State or Other Jurisdiction of Organization Cortigent, Inc. Delaware Nano Precision Medical, Inc. California Vivani Medical Australia Pty Ltd Australia

Offer Letter by and between Jonathan Adams and Cortigent, Inc., dated March 11, 2023.

Exhibit 10.4 March 11, 2023 Jonathan Adams [address] Re: Employment Terms—Chief Executive Officer Dear Jonathan Adams: Cortigent, Inc. (the “Company”) is pleased to offer you full-time employment for the position of President and Chief Executive Officer effective as of March 1, 2023, or any other start date that may be mutually agreeable. In this position you will have leading executive and operat

Nasdaq: VANI www.vivani.com March 2024 Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Se

Exhibit 99.2 Nasdaq: VANI www.vivani.com March 2024 Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "s afe harbor" created by those sections. All statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Vivani Medical, Inc.

Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission Fil

Vivani Medical Appoints Daniel Bradbury to its Board of Directors Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Phar

Exhibit 99.1 FOR IMMEDIATE RELEASE Vivani Medical Appoints Daniel Bradbury to its Board of Directors Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Pharmaceuticals, with partner Alkermes, secured in 2012 approval of Bydureon® (exenatide injection), the world’s first

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 Vivani Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

Form of Securities Purchase Agreement dated March 1, 2024.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 1, 2024, between Vivani Medical, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set

Placement Agency Agreement dated March 1, 2024.

Exhibit 10.2 PLACEMENT AGENCY AGREEMENT March 1, 2024 Maxim Group LLC 300 Park Avenue, 6th Floor New York, NY 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Vivani Medical, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $15,000,000 of registered securities of the Company, including, but not limited

Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants

Exhibit 99.1 Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants ALAMEDA, Calif., March 1, 2024-(BUSINESS WIRE)- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced that it has entered into a securities purchase agr

Form of Warrant.

Exhibit 4.1 COMMON STOCK PURCHASE WARRANT vivani medical, inc. Warrant Shares: []Initial Exercise Date: March [], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “In

3,947,368 Shares of Common Stock Warrants to Purchase up to 3,947,368 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256904 Prospectus Supplement (to Prospectus dated June 14, 2021) 3,947,368 Shares of Common Stock Warrants to Purchase up to 3,947,368 Shares of Common Stock We are offering an aggregate of 3,947,368 shares of our common stock, par value $0.0001 per share (the “Common Stock”) and warrants to purchase up to 3,947,368 shares of our Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): February 28, 2024 Vivani Medical, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): February 28, 2024 Vivani Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission Fil

Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio NPM-115 (exenatide implant) generated significant weight los

Exhibit 99.1 FOR IMMEDIATE RELEASE Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio NPM-115 (exenatide implant) generated significant weight loss comparable to injectable semaglutide (Ozempic®/Wegovy®) from a single administration with expected twice-yearly d

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI www.vivani.com February 2024 Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of th

Exhibit 99.2 Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI www.vivani.com February 2024 Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covere

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): January 9, 2024 Vivani Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): December 26, 2023 Vivani Medical, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): December 26, 2023 Vivani Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): November 20, 2023 Vivani Medical, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event Reported): November 20, 2023 Vivani Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation) (Commission Fil

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI November 14, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A o

Exhibit 99.1 Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI November 14, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 VIVANI MEDICAL,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission

Vivani Medical Provides Business Update and Reports Third Quarter Financial Results Company announces addition of NPM-115 (high-dose exenatide implant) to its emerging pipeline, a potential alternative to life-long injections or pills for long-term G

Exhibit 99.2 FOR IMMEDIATE RELEASE Vivani Medical Provides Business Update and Reports Third Quarter Financial Results Company announces addition of NPM-115 (high-dose exenatide implant) to its emerging pipeline, a potential alternative to life-long injections or pills for long-term GLP-1 therapy for the treatment of chronic weight management in obese or overweight patients Vivani is actively enga

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36747 Vivani Medical, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 VIVANI MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commissi

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI September 18, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward -looking statements within the meaning of Section 27A o

Exhibit 99.1 Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI September 18, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward -looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be co

Amendment 1 to the Transition Funding, Support and Services Agreement, by and between the Registrant and Cortigent, Inc., dated August 28, 2023 (incorporated by reference to Exhibit 10.1 in the Registrant’s Current Report on Form 8-K filed with the SEC on August 28, 2023).

Exhibit 10.1 FIRST AMENDMENT TO TRANSITION FUNDING, SUPPORT AND SERVICES AGREEMENT This First Amendment To Transition Funding, Support and Services Agreement (this “First Amendment”) is made and entered into as of August 25, 2023 (the “First Amendment Effective Date”), between Vivani Medical, Inc., a Delaware corporation (“Parent”), and Cortigent, Inc., a Delaware corporation (“Cortigent”). Parent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 VIVANI MEDICAL, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI August 28, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of

Exhibit 99.1 Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI August 28, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be cove

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36747 Vivani Medical, Inc.

Certificate of Conversion, filed by Vivani Medical, Inc. with the Secretary of State of Delaware and effective July 6, 2023

Exhibit 3.4

VIVANI MEDICAL, INC. PLAN OF CONVERSION

Exhibit 99.1 VIVANI MEDICAL, INC. PLAN OF CONVERSION This Plan of Conversion (this “Plan”) sets forth certain terms of the conversion of Vivani Medical, Inc. (f/k/a Second Sight Medical Products, Inc.), a California corporation (the “California Corporation”), to a Delaware corporation (the “Delaware Corporation”), pursuant to the terms of the California Corporations Code (as amended, “CCC”) and th

Certificate of Conversion, filed by Vivani Medical, Inc. with the Secretary of State of California and effective July 5, 2023

Exhibit 3.3

Bylaws of Vivani Medical, Inc. effective July 6, 2023 (incorporated by reference to Exhibit 3.2 in the Registrant’s Current Report on Form 8-K filed with the SEC on July 10, 2023).

Exhibit 3.2 BYLAWS OF VIVANI MEDICAL, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by the Board of Directors, which time, date and place may subsequently be changed at

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 VIVANI MEDICAL, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission File

Certificate of Incorporation of Vivani Medical, Inc., filed with the Secretary of State of Delaware and effective, July 6, 2023 (incorporated by reference to Exhibit 3.1 in the Registrant’s Current Report on Form 8-K filed with the SEC on July 10, 2023).

Exhibit 3.1 2 3 4 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 VIVANI MEDICAL, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission Fi

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI May 15, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the

Exhibit 99.1 Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI May 15, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 VIVANI MEDICAL, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Vivani Medical, Inc.

Vivani Medical Reports First Quarter Financial Results and Provides Business Update

Exhibit 99.2 FOR IMMEDIATE RELEASE Vivani Medical Reports First Quarter Financial Results and Provides Business Update May 15, 2023 EMERYVILLE, Calif. - (BUSINESS WIRE) - Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product NPM-119 for the treatment of patients with type 2 diabetes and/

DE:EYES / VIVANI MEDICAL INC / Williams Gregg - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Vivani Medical, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 92854B 109 (CUSIP Number) 5858 Horton Street, Suite 280 Emeryville, CA 94608 (818) 833-5000 (Name, Address and Telephone Number of Person Authorized to Recei

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

DE:EYES / VIVANI MEDICAL INC / Bolck Joachim Eberhard - SC 13D Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) Vivani Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92854B 109 (CUSIP Number) Andrew D. Hudders, Esq. Golenbock Eiseman Assor Bell & Peskoe LLP, 711 Third A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Vivani Medical, Inc.

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI March 21, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of t

Exhibit 99.1 Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI March 21, 2023 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be cover

Transition Funding, Support and Services Agreement by and between the Registrant and Cortigent, Inc., dated March 19, 2023 (incorporated by reference to Exhibit 10.1 in the Registrant’s Current Report on Form 8-K filed with the SEC on March 21, 2023).

Exhibit 10.1 TRANSITION FUNDING, SUPPORT AND SERVICES AGREEMENT BY AND BETWEEN VIVANI MEDICAL, INC. AND CORTIGENT, INC. Dated as of March 19, 2023 TRANSITION FUNDING, SUPPORT AND SERVICES AGREEMENT This TRANSITION FUNDING, SUPPORT AND SERVICES AGREEMENT (this “Agreement”), dated as of March 19, 2023 (the “Effective Date”), is by and between Vivani Medical, Inc., a California corporation (“Parent”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2023 VIVANI MEDICAL, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2023 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission F

Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division

Exhibit 99.2 FOR IMMEDIATE RELEASE Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division EMERYVILLE, Calif. – (BUSINESS NEWSWIRE) – March 21, 2023 – Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, clinical-stage biopharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 VIVANI MEDICAL,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commissio

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI February 16, 2023 www.vivani.com +

Exhibit 99.1 Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI February 16, 2023 www.vivani.com + Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission

Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI January 6, 2023 www.vivani.com + Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A o

Exhibit 99.1 Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. Nasdaq: VANI January 6, 2023 www.vivani.com + Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 VIVANI MEDICAL,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commissio

Lease Agreement Between 1350 South Loop LLC and the Registrant, dated November 21, 2022 (incorporated by reference to Exhibit 10.1 in the Registrant’s Current Report on Form 8-K filed with the SEC on November 28, 2022).

Exhibit 10.1 1 LEASE AGREEMENT BETWEEN 1350 SOUTH LOOP LLC, a Delaware limited liability company (?LANDLORD?) AND VIVANI MEDICAL, INC., a California corporation (?TENANT?) TABLE OF CONTENTS 1. Basic Lease Information 1 2. Lease Grant 3 3. Adjustment of Commencement Date; Possession 3 4. Rent 4 5. Compliance with Laws; Use 5 6. Security Deposit 6 7. Services to be Furnished by Landlord 7 8. Premise

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commissio

Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates

Exhibit 99.1 Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates Emeryville, CA. - (BUSINESS WIRE) - Nov. 14, 2022 ? Vivani Medical, Inc. (Nasdaq: VANI) (?Vivani? or the ?Company?), a biopharmaceutical company developing miniaturized, long-term drug implants including lead asset NPM-119 for the treatment of patients with type 2 diabetes, today announced financial result

List of Subsidiaries*

EXHIBIT 21.1 SUBSIDIARIES OF VIVANI MEDICAL, INC. Second Sight Medical Products (Switzerland) S?rl (Switzerland) Nano Precision Medical, Inc.

Non-Employee Director Compensation Policy*

Exhibit 10.2 Non-Employee Director Compensation Policy Directors of Vivani Medical, Inc. (the ?Company?) that are not employees of the Company or one of its subsidiaries receive compensation for their services to the Board of Directors and related committees as set forth below. Annual Cash Retainer Fees Effective September 1, 2022, the annual cash retainer fees for non-employee Directors of the Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Vivani Medical, Inc.

Vivani Medical to Present at the ThinkEquity Investor Conference

Exhibit 99.2 FOR IMMEDIATE RELEASE Vivani Medical to Present at the ThinkEquity Investor Conference EMERYVILLE, Calif. ? (BUSINESS NEWSWIRE) ? Oct. 17, 2022 ? Vivani Medical, Inc. (NASDAQ: VANI) (the ?Company? or ?Vivani?), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, announced today that it will present at the upcoming ThinkEquity in

Vivani Medical, Inc. combination of Nano Precision Medical and Second Sight Medical Products Nasdaq: VANI October 17, 2022 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements withi

Exhibit 99.1 Vivani Medical, Inc. combination of Nano Precision Medical and Second Sight Medical Products Nasdaq: VANI October 17, 2022 www.vivani.com Disclaimers The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amende

Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission

Vivani Medical, Inc. combination of Nano Precision Medical and Second Sight Medical Products Nasdaq: VANI September 22, 2022 Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meani

Exhibit 99.1 Vivani Medical, Inc. combination of Nano Precision Medical and Second Sight Medical Products Nasdaq: VANI September 22, 2022 Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which ar

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2022 VIVANI MEDICAL, INC.

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0080 Washington, D.

See accompanying notes to financial statements.

Exhibit 99.2 FINANCIAL INFORMATION Financial Statements (unaudited) Condensed Balance Sheets as of June 30, 2022 and December 31, 2021 1 Condensed Statements of Operations for the three and six months ended June 30, 2022 and 2021 2 Condensed Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2022 and 2021 2 Condensed Statements of Stockholders? Equity for e

Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)

Exhibit 99.1 FOR IMMEDIATE RELEASE Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI) Emeryville, CA ? (BUSINESS NEWSWIRE) ? August 31, 2022 ? Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ: VANI) (the ?Company? or ?Vivani?) announced that trading of the Company?s common stock on The Nasdaq Capital Market under the symbol ?VANI? will commence today. Vivani is the c

Vivani Medical, Inc. 2022 Omnibus Incentive Plan

Exhibit 99.1 VIVANI MEDICAL, INC. 2022 OMNIBUS INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Vivani Medical, Inc. 2022 Omnibus Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Vivani Medical, Inc. (f/k/a Second Sight Medical Products, Inc.) (the ?Compan

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Unless the context otherwise requires, all references in this section to Second Sight refer to Second Sight Medical Products, Inc. and all references to NPM refer to Nano Precision Medical before giving effect to the Agreement and Plan of Merger and Reorganization, dated as of February 4, 2022. References to Vivani refers to

Waiver of SHA Termination Closing Condition dated August 30, 2022

Exhibit 2.3 WAIVER OF CLOSING CONDITION UNDER MERGER AGREEMENT Reference is made to that certain Agreement and Plan of Merger, dated as of February 4, 2022 (the ?Agreement?), by and among Second Sight Medical Products, Inc., a California corporation (the ?Company?), Nano Precision Medical, Inc., a California corporation (?NPM?), and NPM Acquisition Corp., a California corporation. Capitalized term

As filed with the Securities and Exchange Commission on September 2, 2022

As filed with the Securities and Exchange Commission on September 2, 2022 Registration No.

Certificate of Amendment, filed August 25, 2022, and effective August 30, 2022 changing the name of the Company to “Vivani Medical, Inc.” (incorporated by reference Exhibit 3.1 in the Company’s Current Report on Form 8-K filed with the SEC on September 2, 2022)

Exhibit 3.1 California Secretary of State Business Programs Division 1500 11th Street, Sacramento, CA 95814 Request Type: Entity Name: Entity No.: Entity Type: Issuance Date: Copies Requested: Receipt No.: Certified Copies SECOND SIGHT MEDICAL PRODUCTS, INC. 08/25/2022 1 CALIFORNIA 2536744 Stock Corporation - CA - General 002438198 Formed In: Certificate No.: 040203220 Document Listing Reference #

Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 VIVANI MEDICAL, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation) (Commission

EYES / Second Sight Medical Products Inc / Williams Gregg - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Vivani Medical, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 81362J100 (CUSIP Number) 13170 Telfair Avenue Sylmar, CA 91342 (818) 833-5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and

Consent of Venable LLP (included in Exhibit 5.1 hereto and incorporated herein by reference)

Exhibit 5.01 September 2, 2022 Vivani Medical, Inc. 5858 Horton Street, Suite 280 Emeryville, CA 94608 Ladies and Gentlemen, We have acted as special counsel to Vivani Medical, Inc., a California corporation, (the ?Company?) in connection with the Company?s Registration Statement on Form S-8 (the ?Registration Statement?) filed by the Company with the Securities and Exchange Commission (the ?Commi

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEES TABLE FORM S-8 (Form Type) Vivani Medical, Inc.

VANI / Vivani Medical Inc / Mendelsohn Adam - SC 13D Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a) Vivani Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92854B 109 (CUSIP Number) Andrew D. Hudders, Esq. Golenbock Eiseman Assor Bell & Peskoe LLP, 711 Third A

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporatio

Certificate of Amendment to Restated Articles of Incorporation, as amended, of Second Sight Medical Products, Inc., dated July 27, 2022 and effective August 9, 2022.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED ARTICLES OF INCORPORATION, AS AMENDED OF SECOND SIGHT MEDICAL PRODUCTS, INC. Gregg Williams and Scott Dunbar hereby certify that: 1. They are the Chairman of the Board and Secretary, respectively, of Second Sight Medical Products, Inc. (the ?Corporation?), a California corporation, with California Entity Number 2536744. 2. Article III of the Res

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Second Sight Medical Products, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation

Other Events, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation)

Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting Second Sight to change its name to Vivani Medical, Inc.

Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting Second Sight to change its name to Vivani Medical, Inc. Los Angeles, CA ? (BUSINESS NEWSWIRE) ? July 29, 2022 ? Second Sight Medical Products, Inc. (NASDAQ: EYES) (the ?Company? or ?Second Sight?), a lea

Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting Second Sight to change its name to Vivani Medical, Inc.

Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting Second Sight to change its name to Vivani Medical, Inc. Los Angeles, CA ? (BUSINESS NEWSWIRE) ? July 29, 2022 ? Second Sight Medical Products, Inc. (NASDAQ: EYES) (the ?Company? or ?Second Sight?), a lea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 SECOND SIGHT MEDICA

425 1 g0831138-k.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other juris

EYES / Second Sight Medical Products Inc / Williams Gregg - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Second Sight Medical Products, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 81362J100 (CUSIP Number) 13170 Telfair Avenue Sylmar, CA 91342 (818) 833-5000 (Name, Address and Telephone Number of Person Authorized to Recei

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 g083087defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p

Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study Grant proceeds support an ongoing early feasibility study of Orion

Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study Grant proceeds support an ongoing early feasibility study of Orion Los Angeles, CA ? (BUSINESS NEWSWIRE) ? July 18, 2022 ? Second Sight Medical Products, Inc. (NASDAQ: EYES) (the ?Company? or ?Second Sight?), a leading developer of implantable visual prostheses that are intended to c

Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study Grant proceeds support an ongoing early feasibility study of Orion

Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study Grant proceeds support an ongoing early feasibility study of Orion Los Angeles, CA ? (BUSINESS NEWSWIRE) ? July 18, 2022 ? Second Sight Medical Products, Inc. (NASDAQ: EYES) (the ?Company? or ?Second Sight?), a leading developer of implantable visual prostheses that are intended to c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 SECOND SIGHT MEDICA

425 1 g0830848k.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisd

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT

424B3 1 tm2214685-6424b3.htm 424B3 TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(3)  Registration No. 333-264959 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Shareholders of Second Sight Medical Products, Inc.: Second Sight Medical Products, Inc. (“Second Sight”) and Nano Precision Medical, Inc. (“NPM”) have entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

Second Sight Medical Products, Inc. 13170 Telfair Ave Sylmar, CA 91342

CORRESP 1 filename1.htm Second Sight Medical Products, Inc. 13170 Telfair Ave Sylmar, CA 91342 June 22, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Michael Davis Division of Corporation Finance Office of Life Sciences Re: Second Sight Medical Products, Inc. Registration Statement on Form S-4 Filed May 13, 2022 (a

Waiver of Available Cash Requirement to the Merger Agreement dated June 15, 2022 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 21, 2022).

Exhibit 2.1 Waiver of Available Cash Requirement This waiver is made on June 15, 2022, and applies to the Agreement and Plan of Merger between Second Sight Medical Product, Inc. and Nano Precision Medical, Inc., dated February 4, 2022 (the ?Merger Agreement?). Whereas the Merger agreement requires that the Available Cash shall not be less than $64,000,000, less the amount of any advance made by SS

Waiver of Available Cash Requirement to the Merger Agreement dated June 15, 2022

Exhibit 2.1 Waiver of Available Cash Requirement This waiver is made on June 15, 2022, and applies to the Agreement and Plan of Merger between Second Sight Medical Product, Inc. and Nano Precision Medical, Inc., dated February 4, 2022 (the ?Merger Agreement?). Whereas the Merger agreement requires that the Available Cash shall not be less than $64,000,000, less the amount of any advance made by SS

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 SECOND SIGHT MEDICA

425 1 g0830608k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisd

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation)

Waiver of Available Cash Requirement to the Merger Agreement dated June 15, 2022

Exhibit 2.2 Waiver of Available Cash Requirement This waiver is made on June 15, 2022, and applies to the Agreement and Plan of Merger between Second Sight Medical Product, Inc. and Nano Precision Medical, Inc., dated February 4, 2022 (the ?Merger Agreement?). Whereas the Merger agreement requires that the Available Cash shall not be less than $64,000,000, less the amount of any advance made by SS

As filed with the Securities and Exchange Commission on June 16, 2022

Table of Contents As filed with the Securities and Exchange Commission on June 16, 2022 Registration No.

Form of Proxy Card of Second Sight Medical Products, Inc.

Exhibit 99.1 YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: Second Sight Medical Products, Inc. Special Meeting of Shareholders For Shareholders of record as of XX XX, 2022 TIME: XX XX XX 2022 XX AM, Pacific Time PLACE: Annual Meeting to be held live via the Internet. Please visit www.proxydocs/EYES for more details. This proxy is being solicited on behalf of the Board of Directors The undersigned hereby

June 7, 2022

Exhibit 99.1 June 7, 2022 Re: Notice of Record Date for Shareholder Vote on Fundamental Transaction Dear Warrant Holder: Reference is made to the Warrant Agreement (the ?Agreement?) by and between Second Sight Medical Products, Inc. (?Second Sight?) and VStock Transfer, LLC (the ?Warrant Agent?) (https://www.sec.gov/Archives/edgar/data/1266806/000161577417000080/s105077ex4-4.htm). Capitalized term

June 7, 2022

Exhibit 99.1 June 7, 2022 Re: Notice of Record Date for Shareholder Vote on Fundamental Transaction Dear Warrant Holder: Reference is made to the Warrant Agreement (the ?Agreement?) by and between Second Sight Medical Products, Inc. (?Second Sight?) and VStock Transfer, LLC (the ?Warrant Agent?) (https://www.sec.gov/Archives/edgar/data/1266806/000161577417000080/s105077ex4-4.htm). Capitalized term

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 SECOND SIGHT MEDICAL

425 1 g0830518k.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdi

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact name of registrant as specified in its charter) California 001-36747 02-0692322 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Second Sight Medical Products, Inc.

Amendment to Restated Articles of Incorporation of the Registrant

Exhibit 3.2 ? ? ? A0830657 ? FILED ? Secretary of State ? State of California ? JUL 03 2019 ? Certificate of Amendment to the Restated Articles of Incorporation of Second Sight Medical Products, Inc. (Pursuant to Section 902 of the California Corporations Code) The undersigned president and secretary of Second Sight Medical Products, Inc., a corporation organized and existing under the laws of the

Consent of Adam Mendelsohn

Exhibit 99.2 May 9, 2022 Second Sight Medical Products, Inc. 13170 Telfair Ave Sylmar, CA, 91342 Consent to Reference in Registration Statement Second Sight Medical Products, Inc. (the ?Company?) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?). In connection therewith, I hereby consent, p

Form of Lock-Up Agreement (incorporated by reference to the registrant’s proxy statement/prospectus on Form S-4, file no. 333-264959, originally filed with the Securities and Exchange Commission on May 13, 2022)

EX-10.15 3 eyes-20211231xex10d15.htm EXHIBIT-10.15 Exhibit 10.15 Lock-Up Agreement [ ], 2022 Second Sight Medical Products, Inc. 13170 Telfair Avenue Sylmar, California 91342 Attention Scott Dunbar, Acting Chief Executive Officer Ladies and Gentlemen: In connection with Section 7.7 of that certain Agreement and Plan of Merger among Second Sight Medical Products, Inc. (“SSMP”) and Nano Precision Me

Form of Proxy Card of Second Sight Medical Products, Inc.

Exhibit 99.1 ? YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: Second Sight Medical Products, Inc. Special Meeting of Shareholders For Shareholders of record as of XX XX, 2022 TIME: XX XX XX 2022 XX AM, Pacific Time PLACE: Annual Meeting to be held live via the Internet. Please visit www.proxydocs/EYES for more details. This proxy is being solicited on behalf of the Board of Directors The undersigned here

As filed with the Securities and Exchange Commission on May 13, 2022

Table of Contents ? As filed with the Securities and Exchange Commission on May 13, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables ? Form S-4 (Form Type) ? SECOND SIGHT MEDICAL PRODUCTS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Second Sight Medical Products, Inc.

Merger Agreement dated February 4, 2022

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among SECOND SIGHT MEDICAL PRODUCTS, INC., and NANO PRECISION MEDICAL, INC. Dated as of February 4, 2022 TABLE OF CONTENTS Page Section 1. DESCRIPTION OF TRANSACTION 1 1.1 Structure of the Merger 1 1.2 Effects of the Merger 1 1.3 Closing; Effective Time 2 1.4 Articles of Incorporation and Bylaws; Directors and Officers 2 1.5 Intentionally

SAFE Agreement, dated February 4, 2022, between Registrant and Nano Precision Medical, Inc. (incorporated by reference to registrant’s current report on Form 8-K filed with the Securities and Exchange Commission on February 8, 2022)

Exhibit 10.1 THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTI

SAFE Agreement dated February 4, 2022

Exhibit 10.1 THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTI

Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in its Charter) California 001-36747 02-0692322 (State or Other Jurisdiction of Incorporati

Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company

Exhibit 99.1 Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company ? Nano Precision Medical?s lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes ? Second Sight will issue 134M shares to acquire full ownership of Nano Precision Medical. Second Sight sharehold

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):February 4, 2022 SECOND SIGHT MEDI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):February 4, 2022 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in its Charter) California 001-36747 02-0692322 (State or Other Jurisdiction of Incorporatio

February 8, 2022 Second Sight Medical Products Proposed Merger With Nano Precision Medical Forward Looking Statement The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27 A o

Exhibit 99.2 February 8, 2022 Second Sight Medical Products Proposed Merger With Nano Precision Medical Forward Looking Statement The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended, which are intended to be

Agreement and Plan of Merger by and among Second Sight Medical Products, Inc. and Nano Precision Medical, Inc., dated February 4, 2022 (incorporated by reference to Exhibit 2.1 in the Registrant’s Current Report on Form 8-K filed with the SEC on February 8, 2022).

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among SECOND SIGHT MEDICAL PRODUCTS, INC., and NANO PRECISION MEDICAL, INC. Dated as of February 4, 2022 TABLE OF CONTENTS Page Section 1. DESCRIPTION OF TRANSACTION 1 1.1 Structure of the Merger 1 1.2 Effects of the Merger 1 1.3 Closing; Effective Time 2 1.4 Articles of Incorporation and Bylaws; Directors and Officers 2 1.5 Intentionally

Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company

Exhibit 99.1 Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company ? Nano Precision Medical?s lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes ? Second Sight will issue 134M shares to acquire full ownership of Nano Precision Medical. Second Sight sharehold

February 8, 2022 Second Sight Medical Products Proposed Merger With Nano Precision Medical Forward Looking Statement The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27 A o

Exhibit 99.2 February 8, 2022 Second Sight Medical Products Proposed Merger With Nano Precision Medical Forward Looking Statement The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended, which are intended to be

EYES / Second Sight Medical Products Inc / Empery Asset Management, LP - SECOND SIGHT MEDICAL PRODUCTS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Second Sight Medical Products, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 81362J209 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Second Sight Medical Products, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Second Sight Medical Products, Inc.

Other Events

8-K 1 g0822878k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 29, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in Its Charter) California (State or Other Jurisdiction of Incorporation

Letter from Gumbiner Savett, Inc.to the Securities and Exchange Commission dated July 2, 2021.

Exhibit 16.1 July 2, 2021 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We are the former independent registered public accounting firm for Second Sight Medical Products, Inc. and Subsidiary (the ?Company?). We have read the Company?s disclosure set forth in Item 4.01 ?Changes in Registrant?s Certifying Accountant? of the Company?s Current Repo

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in its Charter) California 001-36747 02-0692322 (State or Other Jurisdiction of Incorporation)

Form of Lock Up Agreement (incorporated by reference to registrant’s current report on Form 8-K filed with the Securities and Exchange Commission on June 28, 2021)

Exhibit 10.1 Form of Lock-Up Agreement [?], 2021 ThinkEquity A Division of Fordham Financial Management, Inc. 17 State Street, 22nd Fl New York, NY 10004 Ladies and Gentlemen: The undersigned understands that ThinkEquity, a division of Fordham Financial Management, Inc., (the ?Representative?) proposes to enter into an Underwriting Agreement (the ?Underwriting Agreement?) with Second Sight Medical

EYES / Second Sight Medical Products Inc / Empery Asset Management, LP - SECOND SIGHT MEDICAL PRODUCTS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Second Sight Medical Products, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 81362J209 (CUSIP Number) June 22, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi

Second Sight Medical Products Announces Closing of Public Offering

Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Medical Products Announces Closing of Public Offering Los Angeles, CA ? (BUSINESS NEWSWIRE) June 25 , 2021 ? Second Sight Medical Products, Inc. (NASDAQ: EYES) (?Second Sight? or the ?Company?), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced

Form of Underwriting Agreement, dated June 22, 2021, between Registrant and ThinkEquity LLC (incorporated by reference to the registrant’s Current Report on Form 8-K, originally filed with the Securities and Exchange Commission on June 28, 2021)

EX-1.1 2 g082246ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 UNDERWRITING AGREEMENT between SECOND SIGHT MEDICAL PRODUCTS, INC. and ThinkEquity, a division of Fordham Financial Management, Inc., as Representative of the Several Underwriters SECOND SIGHT MEDICAL PRODUCTS, INC. UNDERWRITING AGREEMENT New York, New York June 22, 2021 ThinkEquity, A Division of Fordham Financial Management, Inc. As Representativ

Entry into a Material Definitive Agreement, Other Events

8-K 1 g0822468k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in its Charter) California 001-36747 02-0692322 (State or Other Jurisd

Second Sight Medical Products Announces Proposed Public Offering of Common Stock

EX-99.1 2 g082238ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Medical Products Announces Proposed Public Offering of Common Stock Los Angeles, CA – (BUSINESS NEWSWIRE) – June 22, 2021 - Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”) a leading developer of implantable visual prosthetics that are intended to create an artificial form o

ThinkEquity a division of Fordham Financial Management, Inc. The date of this prospectus supplement is June 22, 2021. Prospectus Supplement

Filed pursuant to Rule 424(b)(5) Registration No. 333-256904 PROSPECTUS SUPPLEMENT (To prospectus dated June 14, 2021) 10,000,000 Shares Common Stock Second Sight Medical Products, Inc. We are offering 10,000,000 shares of our common stock, no par value per share, at a price of $5.00 per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on th

Other Events, Financial Statements and Exhibits

8-K 1 g0822388k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in its Charter) California 001-36747 02-0692322 (State or Other Jurisd

Second Sight Medical Products Announces Pricing of Public Offering

EX-99.2 3 g082238ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Second Sight Medical Products Announces Pricing of Public Offering Los Angeles, CA – (BUSINESS NEWSWIRE) June 22 , 2021 — Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful visio

Second Sight Medical Products, Inc.

Filed pursuant to Rule 424(b)(5) Registration No. 333-256904 The information in this preliminary prospectus supplement, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to

Other Events

8-K 1 eyes-8k20210621.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 18, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in Its Charter) California (State or Other Jurisdiction of Incorpo



Via EDGAR June 11, 2021 ?? U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jane Park ? ? ? ? Re: Second Sight Medical Products, Inc. ? Registration Statement on Form S-3 ? Filed June 8, 2021 ? File No. 333-256904 Acceleration Request ? ? Requested Date: June 14, 2021 ? Requested Time: 4:00 PM

As filed with the Securities and Exchange Commission on June 8, 2021

S-3 1 eyes-s3.htm S-3 As filed with the Securities and Exchange Commission on June 8, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Second Sight Medical Products, Inc. (Exact name of registrant as specified in its charter) California (State or other jurisdiction of incorporation or

Other Events

8-K 1 eyes-8k20210601.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 1, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in Its Charter) California (State or Other Jurisdiction of Incorpor

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 1, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC.

Financial Statements and Exhibits, Other Events

8-K 1 eyes-8k20210601.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 28, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in Its Charter) California (State or Other Jurisdiction of Incorpor

Second Sight Medical Products Announces Results of its 2021 Annual Meeting

Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Medical Products Announces Results of its 2021 Annual Meeting Los Angeles, CA ? (BUSINESS NEWSWIRE) ? June 1, 2021 ? Second Sight Medical Products, Inc. (NASDAQ: EYES) (the ?Company? or ?Second Sight?), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36747 Second Sight Medical Products, Inc.

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

4,650,000 Shares of Common Stock ______________

Filed Pursuant to Rule 424(b)(3) Registration No. 333-255267 PROSPECTUS 4,650,000 Shares of Common Stock This prospectus relates to the offer and sale from time to time by the selling shareholders named in this prospectus of up to an aggregate of 4,650,000 issued and outstanding shares of the common stock of Second Sight Medical Products, Inc. We are not selling any shares of our common stock unde



CORRESP 1 filename1.htm Via EDGAR April 27, 2021  U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Alan Campbell     Re: Second Sight Medical Products, Inc.  Registration Statement on Form S-3  Filed April 16, 2021  File No. 333-255267 Acceleration Request   Requested Date: April 28, 2021  Requested Time:

Annual Report - 10-K/A

10-K/A 1 eyes-10ka20201231.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM

Restated Articles of Incorporation of Second Sight Medical Products, Inc., as amended

Exhibit 3.1 RESTATED ARTICLES OF INCORPORATION OF SECOND SIGHT MEDICAL PRODUCTS, INC. I The name of the corporation is: SECOND SIGHT MEDICAL PRODUCTS, INC. II The purpose of the corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of California other than the banking business, the trust company business or the practice of

- S-3

S-3 1 eyes-s3.htm S-3 As filed with the Securities and Exchange Commission on April 15, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Second Sight Medical Products, Inc. (Exact name of registrant as specified in its charter) California (State or other jurisdiction of incorporation

Description of Capital Stock (incorporated by reference to the registrant’s Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on April 14, 2021)

EX-4.5 2 eyes-ex459.htm EX-4.5 EXHIBIT 4.5 DESCRIPTION OF SECURITIES OF SECOND SIGHT MEDICAL PRODUCTS, INC. REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Our authorized capital stock consists of 300,000,000 shares of common stock, without par value, and 10,000,000 shares of preferred stock, without par value. As of March 31, 2021, we had a total of 27,908,299 shares of c

Annual Report - 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-36747

Other Events

8-K 1 eyes-8k20210407.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 7, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in Its Charter) California (State or Other Jurisdiction of Incorpo

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 5, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC.

Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors

EX-99.1 2 eyes-ex9916.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors Los Angeles, CA – (BUSINESS NEWSWIRE) – April 6, 2021 – Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create

Termination of a Material Definitive Agreement, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 1, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

8-K 1 eyes-8k20210326.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 26, 2021 SECOND SIGHT MEDICAL PRODUCTS, INC. (Exact Name of Registrant as Specified in Its Charter) California (State or Other Jurisdiction of Incorp

Second Sight Medical Products Names Scott Dunbar Acting CEO

Exhibit 99.1 FOR IMMEDIATE RELEASE Second Sight Medical Products Names Scott Dunbar Acting CEO April 1, 2021 Los Angeles, CA – (BUSINESS NEWSWIRE) – April 1, 2021 – Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individu